secwatch.observer — SEC 8-K summary
======================================

Issuer:     MESA LABORATORIES INC /CO/ (MLAB)
CIK:        0000724004
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001437749-21-025178
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mesa Labs Q2 FY22 revenue $35.84M (+12%), net income up 39% to $3.72M
---------------------------------------------------------------------

- Revenue $35.84M (+12% YoY); operating income $4.20M (-6%); net income $3.72M (+39%); diluted EPS $0.70 vs $0.51.
- Sterilization & Disinfection Control organic growth 21%; Biopharma Development organic growth 16%; Continuous Monitoring revenue record (+18%).
- Instrument division revenue down 8% due to component supply and labor constraints; backlog increased.
- Non-GAAP adjusted operating income $9.997M (flat YoY); adjusted diluted EPS $1.87 vs $1.91.
- Completed acquisition of Agena Bioscience on Oct 20, 2021, adding Clinical Genomics capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724004/000143774921025178/0001437749-21-025178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724004/000143774921025178/mlab20211103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-025178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer